Insulin Glulisine, Diabetes Mellitus Type 1

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To provide local data on efficacy and safety of insulin glulisine in patients with Type 1 Diabetes Mellitus receiving insulin glargine as basic insulin therapy

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Insulin; Insulin glulisine; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Diabetes mellitus, Type 1

• HbA1c 6.5-11.0%

• BMI <35 kg/m²

Exclusion Criteria:

• Diabetes mellitus, Type 2

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.